申请人:Novo Nordisk A/S
公开号:US05166155A1
公开(公告)日:1992-11-24
1-carboxyalkylquinoxaline-2,3(1H,4H)-dione compounds or tautomeric forms thereof of the formula ##STR1## wherein R represents hydrogen, C.sub.1-6 -alkyl, including branched chains, or aralkyl and n represents the number from 0 to 5; R.sup.4 represents hydrogen or hydroxy; R.sup.5, R.sup.6, R.sup.7 and R.sup.8 independently represent hydrogen, nitro, halogen, alkoxy, aryloxy, aralkoxy, C.sub.1-6 -alkyl including branched chains, or aryl; R.sup.9 represents hydrogen, lower alkyl, or aryl; R.sup.10 represents hydrogen, or alkyl. The compounds are useful in the treatment of neurological and psychiatric diseases.
1-羧基烷基喹喔啉-2,3(1H,4H)-二酮化合物或其互变异构体,其化学式为##STR1##其中,R表示氢、C.sub.1-6-烷基(包括支链)或芳基烷基,n表示0到5的数字;R.sup.4表示氢或羟基;R.sup.5、R.sup.6、R.sup.7和R.sup.8独立地表示氢、硝基、卤素、烷氧基、芳氧基、芳基烷氧基、C.sub.1-6-烷基(包括支链)或芳基;R.sup.9表示氢、低碳基或芳基;R.sup.10表示氢或烷基。这些化合物可用于治疗神经和精神疾病。